SCHEMBL9961314

SCHEMBL9961314

C/C=C/CCOC(=O)C1(c2ccc(OC)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 2/20 0.53
▸ CHRM2 P08172 1/20 0.53
▸ CHRM5 P08912 1/20 0.50
▸ CHRM3 P20309 1/20 0.50
▸ SIGMAR1 Q99720 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TET3 O43151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ FBXL19 Q6PCT2 1/20 0.41
▸ CXXC5 Q7LFL8 1/20 0.41
▸ TET1 Q8NFU7 1/20 0.41
▸ KDM2B Q8NHM5 1/20 0.41
▸ CXXC4 Q9H2H0 1/20 0.41
▸ KDM2A Q9Y2K7 1/20 0.41
▸ APOBEC3A P31941 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28318807 0.80 OPRM1 (0.57) CHRM1CHRM2SMN1; SMN2LMNANPSR1
SCHEMBL13869027 0.80 CHRM1 (0.67) CHRM1CHRM2CHRM5CHRM3SIGMAR1
SCHEMBL837139 0.76 ALDH1A1 (0.55) CHRM1CHRM2CHRM5CHRM3SMN1; SMN2
SCHEMBL11219532 0.75 OPRM1 (0.58) CHRM1CHRM2CHRM5CHRM3SIGMAR1
SCHEMBL301027 0.71 KMT2A (0.64) SMN1; SMN2ALDH1A1TET3KMT2AFBXL19
SCHEMBL12170296 0.71 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1TET3KMT2AFBXL19
SCHEMBL10351842 0.70 OPRM1 (0.53) CHRM1CHRM2
SCHEMBL10351516 0.70 OPRM1 (0.53) CHRM1CHRM2
SCHEMBL13545164 0.70 ALDH1A1 (0.52) CHRM1CHRM2SMN1; SMN2ALDH1A1TET3
SCHEMBL8586765 0.70 KDM4E (0.58) CHRM1CHRM2SIGMAR1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202901-B2 Compounds that stimulate glucose utilization and methods of use THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2012-06-19 — — US disclosed
US-8202901-B2 Compounds that stimulate glucose utilization and methods of use THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2012-06-19 — — US disclosed
US-20090258835-A1 COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC EDMONTON (CA) 2009-10-15 — — US disclosed
US-20090258835-A1 COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC EDMONTON (CA) 2009-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258835-A1 COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE GPR119, SLC2A4, SLC2A1 CHRM1 62/4885CHRM2 121/4885CHRM5 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback